Browsing Tag

TULSAPRO

Four Year Follow-Up Data from Profound Medical’s TACT Pivotal Clinical Trial Confirm…

Eli Pacheco Sep 26, 2022 0

TORONTO, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and…

Health

Profound Medical Provides TULSA-PRO® Reimbursement Update

Eli Pacheco Sep 2, 2022 0

TORONTO, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and…

Health

TULSA-PRO® Was Front and Center at AUA2022

Eli Pacheco May 18, 2022 0

TORONTO, May 17, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets…